Compare FMC Corp (FMC) vs Levi Strauss & Co. (LEVI) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

Levi Strauss (LEVI) trades at $24.85, up 4.46% over 24 hours, with strong fundamentals including a 61.72% gross margin and 9.66% net margin. The stock shows bullish earnings momentum, beating estimates in Q2 2026 with $0.28 EPS versus $0.24 expected, and raised full-year guidance. Technicals are mixed with a bearish overall signal but bullish moving averages, while analyst consensus is strongly positive with 15 buy ratings and a $28.00 price target.

LEVI presents a compelling investment case driven by robust profitability, consistent earnings beats, and dividend growth, though near-term headwinds include tariff pressures and foreign exchange volatility. The stock's current price near support at $24 offers potential upside to the consensus target, but investors should monitor competitive dynamics and macroeconomic risks affecting consumer discretionary spending.